MA32731B1 - Céphalosporine possédant un groupe catéchol - Google Patents

Céphalosporine possédant un groupe catéchol

Info

Publication number
MA32731B1
MA32731B1 MA33798A MA33798A MA32731B1 MA 32731 B1 MA32731 B1 MA 32731B1 MA 33798 A MA33798 A MA 33798A MA 33798 A MA33798 A MA 33798A MA 32731 B1 MA32731 B1 MA 32731B1
Authority
MA
Morocco
Prior art keywords
similar
cepham compound
protected
ester
substituted
Prior art date
Application number
MA33798A
Other languages
Arabic (ar)
English (en)
Inventor
Yasuhiro Nishitani
Kenji Yamawaki
Yusuke Takeoka
Hideki Sugimoto
Shinya Hisakawa
Toshiaki Aoki
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42128829&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32731(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of MA32731B1 publication Critical patent/MA32731B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
    • C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D505/00—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D505/10—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D505/12—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7
    • C07D505/14—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7 with hetero atoms directly attached in position 7
    • C07D505/16—Nitrogen atoms
    • C07D505/18—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof
    • C07D505/20—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D505/24—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen further substituted by doubly-bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/06—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 containing at least one condensed beta-lactam ring system, provided for by groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00, e.g. a penem or a cepham system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'INVENTION PORTE SUR UN COMPOSÉ DE CÉPHÈME REPRÉSENTÉ PAR LA FORMULE (I) [DANS LAQUELLE X REPRÉSENTE N, CH OU C-CL ; T REPRÉSENTE S OU SIMILAIRE ; A ET G REPRÉSENTENT INDÉPENDAMMENT UN ALKYLÈNE INFÉRIEUR OU SIMILAIRE ; B REPRÉSENTE UNE SIMPLE LIAISON OU SIMILAIRE ; D REPRÉSENTE UNE SIMPLE LIAISON, -NR7-CO-, -CO-NR7-, 'NR7-CO-NR7- OU SIMILAIRE ; E REPRÉSENTE UN ALKYLÈNE INFÉRIEUR QUI PEUT ÊTRE SUBSTITUÉ ; F REPRÉSENTE UNE SIMPLE LIAISON OU UN PHÉNYLÈNE QUI PEUT ÊTRE SUBSTITUÉ ; R3, R4, R5 ET R6 REPRÉSENTENT CHACUN INDÉPENDAMMENT UN HYDROGÈNE, UN HALOGÈNE, UN NITRILE OU 'OR8 ; R8 REPRÉSENTE UN HYDROGÈNE OU SIMILAIRE ; ET UN GROUPE REPRÉSENTÉ PAR LA FORMULE (II) REPRÉSENTE UN GROUPE AMMONIUM QUATERNAIRE MONOCYCLIQUE OU À CYCLES CONDENSÉS SATURÉ OU INSATURÉ QUI POSSÈDE AU MOINS UN ATOME N ET QUI PEUT ÊTRE SUBSTITUÉ, LA LIGNE TIRETÉE REPRÉSENTANT UNE LIAISON DANS LE CYCLE], UN ESTER DU COMPOSÉ DE CÉPHÈME, UN PRODUIT PROTÉGÉ DU COMPOSÉ DE CÉPHÈME DANS LEQUEL UN GROUPE AMINO, SITUÉ SUR LE NOYAU DANS LA CHAÎNE DU CÔTÉ DE LA POSITION 7, EST PROTÉGÉ, UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DU COMPOSÉ DE CÉPHÈME, DE L'ESTER OU DU PRODUIT PROTÉGÉ, OU UN SOLVATE DU COMPOSÉ DE CÉPHÈME, DE L'ESTER, DU PRODUIT PROTÉGÉ OU DU SEL PHARMACEUTIQUEMENT ACCEPTABLE, QUI PRÉSENTE UN LARGE SPECTRE ANTIBACTÉRIEN ET EN PARTICULIER QUI PRÉSENTE UNE ACTIVITÉ ANTIBACTÉRIENNE PUISSANTE VIS-À-VIS DE BACTÉRIES À GRAM NÉGATIF PRODUISANT DE LA ß-LACTAMASE. L'INVENTION PORTE ÉGALEMENT SUR UNE COMPOSITION PHARMACEUTIQUE RENFERMANT LE COMPOSÉ DE CÉPHÈME, L'ESTER, LE PRODUIT PROTÉGÉ, LE SEL PHARMACEUTIQUEMENT ACCEPTABLE OU LE SOLVATE.
MA33798A 2008-10-31 2011-04-29 Céphalosporine possédant un groupe catéchol MA32731B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008280828 2008-10-31
PCT/JP2009/068400 WO2010050468A1 (fr) 2008-10-31 2009-10-27 Céphalosporine possédant un groupe catéchol

Publications (1)

Publication Number Publication Date
MA32731B1 true MA32731B1 (fr) 2011-10-02

Family

ID=42128829

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33798A MA32731B1 (fr) 2008-10-31 2011-04-29 Céphalosporine possédant un groupe catéchol

Country Status (38)

Country Link
US (1) US9238657B2 (fr)
EP (2) EP2341053B1 (fr)
JP (2) JP5498393B2 (fr)
KR (1) KR101655961B1 (fr)
CN (1) CN102203100B (fr)
AU (1) AU2009310959B2 (fr)
BR (1) BRPI0921701B8 (fr)
CA (1) CA2736953C (fr)
CL (1) CL2011000939A1 (fr)
CO (1) CO6331443A2 (fr)
CR (1) CR20110144A (fr)
CY (2) CY1118536T1 (fr)
DK (1) DK2960244T3 (fr)
EA (1) EA019520B1 (fr)
ES (2) ES2564836T3 (fr)
FI (1) FIC20200039I1 (fr)
FR (1) FR20C1050I2 (fr)
HR (1) HRP20161408T1 (fr)
HU (2) HUE031802T2 (fr)
IL (1) IL211720A (fr)
LT (2) LT2960244T (fr)
MA (1) MA32731B1 (fr)
ME (1) ME02666B (fr)
MX (1) MX2011004636A (fr)
MY (1) MY155655A (fr)
NL (1) NL301067I2 (fr)
NO (1) NO2020035I1 (fr)
NZ (1) NZ591728A (fr)
PE (1) PE20120010A1 (fr)
PL (1) PL2960244T3 (fr)
PT (1) PT2960244T (fr)
RS (1) RS55365B1 (fr)
SI (1) SI2960244T1 (fr)
SM (1) SMT201600397B (fr)
TW (1) TWI535727B (fr)
UA (1) UA105190C2 (fr)
WO (1) WO2010050468A1 (fr)
ZA (1) ZA201102024B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2702257C (fr) 2007-10-09 2016-07-12 Sopharmia, Inc. Inhibiteurs de beta-lactamase a large spectre
EA019520B1 (ru) 2008-10-31 2014-04-30 Сионоги Энд Ко., Лтд. Цефалоспорины, содержащие катехольную группу
AU2011236933A1 (en) 2010-04-05 2013-05-02 Shionogi & Co., Ltd. Cephem compound having catechol group
CN102918047A (zh) 2010-04-05 2013-02-06 盐野义制药株式会社 具有假儿茶酚基团的头孢烯类化合物
JP5852562B2 (ja) * 2010-04-28 2016-02-03 塩野義製薬株式会社 新規なセフェム誘導体
CN103502218B (zh) * 2011-03-04 2016-08-17 生命科技公司 用于缀合生物分子的化合物和方法
KR101719556B1 (ko) * 2011-03-30 2017-03-24 주식회사 레고켐 바이오사이언스 신규한 세파로스포린 유도체 및 이를 함유하는 의약 조성물
KR20140039202A (ko) 2011-04-28 2014-04-01 시오노기세야쿠 가부시키가이샤 카테콜 또는 의사 카테콜 구조를 갖는 신규 세펨 화합물
WO2013002215A1 (fr) 2011-06-27 2013-01-03 塩野義製薬株式会社 Composé de céphème comportant un groupe pyridinium
TWI547496B (zh) * 2011-10-04 2016-09-01 葛蘭素集團公司 抗菌化合物
WO2013051597A1 (fr) 2011-10-04 2013-04-11 塩野義製薬株式会社 Dérivé céphem ayant un groupe catéchol
UY35103A (es) * 2012-10-29 2014-05-30 Glaxo Group Ltd Compuestos de cefem 2-sustituidos
WO2014069649A1 (fr) 2012-10-29 2014-05-08 Shionogi & Co., Ltd. Procédés de production d'intermédiaires de composés de type 2-alkylcephem
US20150344502A1 (en) * 2012-12-26 2015-12-03 Shionogi & Co., Ltd. Cephem compound
US10376496B2 (en) 2013-09-09 2019-08-13 Merck, Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
HUE042134T2 (hu) 2014-03-24 2019-06-28 Novartis Ag Monobaktám szerves vegyületek bakteriális fertõzések kezelésére
JP6377570B2 (ja) * 2014-04-28 2018-08-22 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ ２−置換セフェム化合物を含有する医薬組成物
KR102396753B1 (ko) 2014-06-11 2022-05-12 베나토알엑스 파마슈티컬스, 인크. 베타-락타마제 억제제
WO2016035846A1 (fr) * 2014-09-04 2016-03-10 塩野義製薬株式会社 Préparation pharmaceutique comprenant une céphalosporine ayant des groupes catéchol
WO2016035847A1 (fr) * 2014-09-04 2016-03-10 塩野義製薬株式会社 Intermédiaire de dérivés de céphalosporine et son procédé de production
HRP20211524T1 (hr) * 2014-09-04 2021-12-24 Shionogi & Co., Ltd. Sol derivata cefalosporina, kristalni kruti oblik istog i postupak za njegovu proizvodnju
CN107709314A (zh) 2015-06-11 2018-02-16 巴斯利尔药物国际股份公司 外排泵抑制剂及其治疗性用途
AU2016327264B2 (en) 2015-09-23 2019-06-27 Novartis Ag Salts and solid forms of monobactam antibiotic
US9751894B2 (en) * 2015-12-10 2017-09-05 Naeja-Rgm Pharmaceuticals Inc. Cephem compounds, their production and use
ES2881776T3 (es) 2016-03-08 2021-11-30 Novartis Ag Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus
CN109310682A (zh) * 2016-06-17 2019-02-05 沃克哈特有限公司 抗菌组合物
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
KR102694317B1 (ko) * 2017-06-09 2024-08-09 포브 신서시스 인코포레이티드 세균 감염의 치료를 위한 카바페넴 화합물 및 조성물
ES2912656T3 (es) * 2017-08-02 2022-05-26 Novartis Ag Proceso para preparar ácido 1-(((Z)-(1-(2-aminotiazol-4-il)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-il)metil)-1-sulfoacetidin-3-il)amino)etiliden)amino)oxi)ciclopropano carboxílico
HUE069183T2 (hu) 2018-02-28 2025-02-28 Novartis Ag 10-(di(fenil)metil)-4-hidroxi-8,9,9a,10-tetrahidro-7H--pirrolo[1',2':4,5]pirazino[1,2-b]piridazin-3,5-dion származékok és kapcsolódó vegyületek mint orthomyxovírus repikáció gátlók influenza kezelésére
US12173018B2 (en) 2018-05-25 2024-12-24 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2020184399A1 (fr) * 2019-03-08 2020-09-17 塩野義製薬株式会社 Composition pharmaceutique antibactérienne
KR20220061163A (ko) 2019-09-06 2022-05-12 나브리바 테라퓨틱스 게엠베하 사이드로포어 세팔로스포린 접합체 및 이의 용도
EP4095141A4 (fr) * 2020-01-22 2023-06-28 Shanghai Senhui Medicine Co., Ltd. Composé céphalosporine antibactérien et son application pharmaceutique
TW202220663A (zh) 2020-07-28 2022-06-01 日商鹽野義製藥股份有限公司 含有具有鄰苯二酚基之頭孢菌素類的凍結乾燥製劑及其製造方法
EP4279491A4 (fr) * 2021-01-12 2024-07-24 Shanghai Senhui Medicine Co., Ltd. Composé antibactérien de céphalosporine et son procédé de préparation
CN113698365A (zh) * 2021-08-30 2021-11-26 成都大学 一种头孢地尔侧链的制备方法
CN121127245A (zh) * 2023-06-01 2025-12-12 江苏恒瑞医药股份有限公司 一种包含头孢类抗菌化合物的药物组合物
CN117024377B (zh) * 2023-08-15 2025-04-29 济南大学 一种2-氯-3,4-二对甲氧苯甲氧基-n-(2-(1-吡咯烷)乙基)苯甲酰胺的制备方法
CN117069638B (zh) * 2023-08-17 2026-02-27 济南大学 一种头孢地尔中间体的制备方法
CN117088764B (zh) * 2023-08-24 2026-01-30 济南大学 一种头孢地尔关键中间体的合成和后处理方法
US12225906B1 (en) 2024-09-26 2025-02-18 Terry Earl Brady Pathogenic affinity pathway of infectious or parasitic organisms for nanogram and picogram dosimetry prophylaxis or cure

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47168A (en) 1974-05-09 1979-07-25 Toyama Chemical Co Ltd Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same
JPS57118588A (en) 1981-11-26 1982-07-23 Toyama Chem Co Ltd Novel cephalosporin
DE3207840A1 (de) 1982-03-04 1983-09-15 Hoechst Ag, 6230 Frankfurt "cephalosporinderivate und verfahren zu ihrer herstellung"
AU2361184A (en) 1983-01-21 1984-07-26 Beecham Group Plc Disubstituted 6-penicillins and 7-cephalosporins
NO165842C (no) 1984-04-23 1991-04-17 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive cefem-forbindelser.
EP0168177A3 (fr) 1984-06-28 1987-04-01 Pfizer Limited Céphalosporines antibiotiques
NO166283C (no) 1985-03-01 1991-06-26 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive 7beta-(2-(5-amino-1,2,4-tiadiazol-3-yl)-2(z)-substituertoksyiminoacetamido)-3-(heterocyclylmetyl)-3-cefem-4-karboksylsyrederivater.
JPH068300B2 (ja) * 1985-08-02 1994-02-02 萬有製薬株式会社 新規セフアロスポリン誘導体
EP0211656A3 (fr) 1985-08-10 1988-03-09 Beecham Group Plc Dérivés de céphalosporine, procédé pour leur préparation et les compositions pharmaceutiques les contenant
JPH07107069B2 (ja) * 1985-09-03 1995-11-15 大塚化学株式会社 セフアロスポリン化合物の新規誘導体、その製造法及び該誘導体を含有する医薬組成物
EP0214600B1 (fr) * 1985-09-03 1992-12-02 Otsuka Kagaku Kabushiki Kaisha Dérivés de céphalosporine
JPS62158291A (ja) * 1986-01-07 1987-07-14 Sagami Chem Res Center セフアロスポリン誘導体
ATE110386T1 (de) 1986-04-14 1994-09-15 Banyu Pharma Co Ltd Cephalosporinderivate, verfahren zu ihrer herstellung und antibakterielle präparate.
EP0346465B1 (fr) 1986-04-14 1993-08-11 Banyu Pharmaceutical Co., Ltd. Derives de 1-carboxy-1-vinyloxyiminoaminothiazole cephalosporine et leur procede de preparation
IE61679B1 (en) 1987-08-10 1994-11-16 Fujisawa Pharmaceutical Co Water-soluble antibiotic composition and water-soluble salts of new cephem compounds
GB8719875D0 (en) 1987-08-22 1987-09-30 Beecham Group Plc Compounds
JPH0228185A (ja) 1988-04-14 1990-01-30 Tanabe Seiyaku Co Ltd セファロスポリン化合物及びその合成中間体
US5149803A (en) * 1988-05-10 1992-09-22 Imperial Chemical Industries Plc Intermediates for cephalosporin compounds
GB8811055D0 (en) 1988-05-10 1988-06-15 Ici Plc Antibiotic compounds
PH25965A (en) 1988-06-06 1992-01-13 Fujisawa Pharmaceutical Co New cephem compounds which have antimicrobial activities
US5244890A (en) 1988-06-06 1993-09-14 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
GB8813945D0 (en) * 1988-06-13 1988-07-20 Fujisawa Pharmaceutical Co New cephem compounds & process for preparation thereof
GB8817653D0 (en) 1988-07-25 1988-09-01 Fujisawa Pharmaceutical Co New cephem compounds & processes for preparation thereof
CA2005787A1 (fr) 1988-12-29 1990-06-29 Masao Wada Composes de cephalosporine
JPH02275886A (ja) 1988-12-29 1990-11-09 Tanabe Seiyaku Co Ltd セファロスポリン化合物及びその製法
US5143910A (en) 1989-09-07 1992-09-01 Shionogi & Co., Ltd. Piperaziniocephalosporins
GB9005246D0 (en) 1990-03-08 1990-05-02 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
US5126336A (en) 1990-08-23 1992-06-30 Bristol-Myers Squibb Company Antibiotic c-3 catechol-substituted cephalosporin compounds, compositions and method of use thereof
US5095012A (en) 1990-08-23 1992-03-10 Bristol-Myers Squibb Company Antibiotic c-7 catechol-substituted cephalosporin compounds, compositions, and method of use thereof
US5234920A (en) 1990-08-23 1993-08-10 Bristol-Myers Squibb Company Antibiotic C-7 catechol-substituted cephalosporin compounds, compositions, and method of use thereof
US5194433A (en) * 1990-11-13 1993-03-16 Bristol-Myers Squibb Company Antibiotic c-3 catechol-substituted cephalosporin compounds, compositions and method of use thereof
GB9111406D0 (en) 1991-05-28 1991-07-17 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
GB9118672D0 (en) 1991-08-30 1991-10-16 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
EP0628562A1 (fr) 1993-06-10 1994-12-14 Roussel Uclaf Céphalosporines comportant en position 7 un radical oxymino substitué, leurs intermédiaires, leurs procédé de préparation et leur application comme médicaments
WO1999033839A1 (fr) 1997-12-26 1999-07-08 Cheil Jedang Corporation Composes derives du cepheme, procede de production associe et composition antibacterienne les contenant
JP2004529132A (ja) 2001-03-27 2004-09-24 アクテリオン　ファマシューティカルズ　リミテッド １，２，３，４−テトラヒドロイソキノリン誘導体
JP2003078440A (ja) 2001-08-30 2003-03-14 Kyocera Corp 高周波スイッチ回路
TW200305422A (en) 2002-03-18 2003-11-01 Shionogi & Co Broad spectrum cefem compounds
WO2003099826A1 (fr) 2002-05-23 2003-12-04 Orchid Chemicals And Pharmaceuticals Limited Nouvelle methode de preparation de cefditorene utilisant le thioester d'acide thiazolylacetique
JP4892926B2 (ja) 2005-10-25 2012-03-07 宇部興産株式会社 スルホン化芳香族ブロック共重合体の製造方法
TW200637559A (en) 2005-03-29 2006-11-01 Shionogi & Co 3-propenylcefem derivative
JP4557859B2 (ja) 2005-09-29 2010-10-06 富士通株式会社 周波数分割多重送受信装置及び送受信方法
WO2007096740A2 (fr) 2006-02-20 2007-08-30 Orchid Research Laboratories Limited Nouvelles céphalosporines
WO2007119511A1 (fr) 2006-03-16 2007-10-25 Astellas Pharma Inc. Composés de céphem et leur utilisation en tant qu'agents antimicrobiens
EA019520B1 (ru) 2008-10-31 2014-04-30 Сионоги Энд Ко., Лтд. Цефалоспорины, содержащие катехольную группу
AU2011236933A1 (en) 2010-04-05 2013-05-02 Shionogi & Co., Ltd. Cephem compound having catechol group
CN102918047A (zh) 2010-04-05 2013-02-06 盐野义制药株式会社 具有假儿茶酚基团的头孢烯类化合物
JP5852562B2 (ja) 2010-04-28 2016-02-03 塩野義製薬株式会社 新規なセフェム誘導体

Also Published As

Publication number Publication date
RS55365B1 (sr) 2017-03-31
LTPA2020530I1 (lt) 2020-11-10
EP2341053A1 (fr) 2011-07-06
LT2960244T (lt) 2016-11-25
EP2341053A4 (fr) 2012-08-08
CN102203100A (zh) 2011-09-28
MX2011004636A (es) 2011-06-20
EP2960244A1 (fr) 2015-12-30
JP5498393B2 (ja) 2014-05-21
BRPI0921701B1 (pt) 2022-05-03
SI2960244T1 (sl) 2017-02-28
HUE031802T2 (en) 2017-08-28
JPWO2010050468A1 (ja) 2012-03-29
TWI535727B (zh) 2016-06-01
FIC20200039I1 (fi) 2020-10-19
ME02666B (fr) 2017-06-20
IL211720A (en) 2015-01-29
IL211720A0 (en) 2011-06-30
NZ591728A (en) 2012-12-21
US20110190254A1 (en) 2011-08-04
BRPI0921701B8 (pt) 2022-11-29
CY2020034I1 (el) 2020-11-25
BRPI0921701A2 (pt) 2020-08-11
WO2010050468A1 (fr) 2010-05-06
JP2014065732A (ja) 2014-04-17
PE20120010A1 (es) 2012-02-07
AU2009310959A1 (en) 2010-05-06
EA019520B1 (ru) 2014-04-30
FR20C1050I2 (fr) 2021-10-15
EP2341053B1 (fr) 2016-01-13
FR20C1050I1 (fr) 2020-11-27
CL2011000939A1 (es) 2011-09-16
SMT201600397B (it) 2017-01-10
LTC2960244I2 (lt) 2023-10-10
NL301067I2 (nl) 2020-10-28
CY1118536T1 (el) 2017-07-12
NO2020035I1 (no) 2020-10-21
MY155655A (en) 2015-11-13
CY2020034I2 (el) 2021-05-05
DK2960244T3 (en) 2016-11-28
EP2960244B1 (fr) 2016-09-14
KR20110090982A (ko) 2011-08-10
US9238657B2 (en) 2016-01-19
CN102203100B (zh) 2014-08-27
ES2602969T3 (es) 2017-02-23
CO6331443A2 (es) 2011-10-20
ES2564836T3 (es) 2016-03-29
PT2960244T (pt) 2016-11-02
AU2009310959B2 (en) 2015-05-07
HRP20161408T1 (hr) 2016-12-02
NL301067I1 (fr) 2020-10-13
EA201170632A1 (ru) 2011-12-30
ZA201102024B (en) 2014-08-27
CA2736953C (fr) 2017-07-11
HUS2000042I1 (hu) 2020-11-30
KR101655961B1 (ko) 2016-09-08
CR20110144A (es) 2011-09-09
PL2960244T3 (pl) 2017-03-31
TW201020259A (en) 2010-06-01
CA2736953A1 (fr) 2010-05-06
UA105190C2 (ru) 2014-04-25

Similar Documents

Publication Publication Date Title
MA33893B1 (fr) Derives de diphenyl-pyrazolopyridines,leur preparation et leur appalication en therapeutique
MA37358A1 (fr) Composition de lutte antiparasitaire comprenant un nouveau dérivé d'iminopyridine
MA27119A1 (fr) Modulateurs tetrahydropyranyle cyclopentyle tetrahydropyrido pyridine de l'activite d'un recepteur de chimiokine
MA34551B1 (fr) Agent de lutte contre des organismes nuisibles
NO20075723L (no) Tiazolforbindelser og fremgangsmater for anvendelse
TNSN07349A1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
EA200500472A1 (ru) Ацетил 2-гидрокси-1,3-диаминоалканы
CA2203618A1 (fr) Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TW200619199A (en) 3-carbamoyl-2-pyridone derivatives
MA27831A1 (fr) Procede pour preparer un analogue de la cyclosporine a
MA29323B1 (fr) Composes de l'acide pyridylacetique
MA30813B1 (fr) Derives de 2-pyridinecarboxamide ayant un effet d'activation sur la gk.
MA28453B1 (fr) Nouveaux insecticides
ATE312100T1 (de) Chinuclidin-verbindungen und medikamente die diese als aktive wirkstoffe enthalten
MA32646B1 (fr) Compositions d'antagonistes de pd -1 et methodes d'utilisation associees
WO2005092858A3 (fr) Composes alpha-aryle ou heteroaryle methyle beta piperidino propanamide en tant qu'antagoniste du recepteur orl1
EA200500814A1 (ru) Производные пирролопиримидина
FR2926554B1 (fr) Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
EA201170632A1 (ru) Цефалоспорины, содержащие катехольную группу
WO2006113615A3 (fr) Agents antimicrobiens et utilisations de ceux-ci
WO2005030766A8 (fr) Composes phenyl-carboxamide utiles pour traiter la douleur
FR2426694A1 (fr) Cephalosporines perfectionnees, leur procede de preparation et leur application therapeutique
MA30540B1 (fr) Derives de quinolines et compositions pharmaceutiques de ces derives.
DK1961734T3 (da) Aminforbindelse og anvendelse deraf til medicinske formål
ATE450511T1 (de) Kristalline formen eines arylanilin-beta-2- adrenergenrezeptor-agonists